BOSTON —
Combined results from two studies of an experimental Alzheimer’s drug suggest it might modestly slow mental decline, especially in patients with mild disease.
Taken separately, the studies missed their main goals to significantly slow the mind-robbing disease. But pooled results found 34 percent less decline in mild Alzheimer’s patients compared to those on a dummy treatment for 18 months.
Doctors say the results do not seem strong enough to win approval of the drug now. But they show researchers are on the right track by trying to clear the sticky deposits that clog patients’ brains.
The drug is being developed by Eli Lilly & Co. and is called solanezumab (sol-ah-NAYZ-uh-mab). Results were reported Monday at an American Neurological Association conference in Boston.
About 35 million people worldwide have dementia, and Alzheimer’s is the most common type. In the U.S., about 5 million have Alzheimer’s. Current medicines such as Aricept and Namenda just temporarily ease symptoms. There is no known cure.
Solanezumab is one of three drugs in late-stage testing that seek to alter the course of Alzheimer’s. The two studies each had about 1,000 patients, about two-thirds with mild disease and one-third with moderately severe Alzheimer’s, in 16 countries. Their average age was 75.
The main measures were two tests, one reflecting language, memory and thinking and the other, ability to perform daily activities such as eating and grooming. The combined results on the mild disease patients showed a nearly 2-point difference in the roughly 90-point score on thinking abilities.
“It’s a small difference,” said Dr. Rachelle Doody of Baylor College of Medicine. She heads a nationwide research network funded by the National Institute on Aging that did an independent analysis of Lilly’s results on the studies and presented them Monday at the conference.
Still, “you slow the decline” with the drug, she said.
Independent experts agreed.
“It’s certainly not the home run we all wanted, but we’re very encouraged by these results,” said Maria Carillo, senior director of medical and scientific relations for the Alzheimer’s Association, which had no role in the research.
A Lilly official said the company will discuss next steps with the Food and Drug Administration.
The price of Lilly shares rose more than 2 percent, or $1.22, to $49.45 in heavy Monday afternoon trading while the Standard & Poor’s 500 index fell slightly. The shares set a new 52-week high price of $49.78 before retreating slightly.
———
Online:
Alzheimer’s info: http://www.alzheimers.gov
Alzheimer’s Association: http://www.alz.org
Health
Alzheimer drug shows some promise in mild disease
- Health
-
-
Her Doctor Dismissed the Lump in Her Breast
It was on the weekend of my 25th birthday that my boyfriend alerted me to a lump in my left breast. At first dismissive of his concern, I eventually promised to see my gynecologist. I was due for my annual exam anyway.
-
Tenn. hospital treats drug-dependent babies
He's less than two weeks old, but he shows the telltale signs of a baby agitated and in pain: an open sore on his chin where he's rubbed the skin raw, along with a scratch on his left check.
-
‘Fibro Fighter’ struggles with fatigue, debilitating pain
For some people life is a little more complicated than the normal rushing around with kids, doing errands, being on time for work and other everyday routines that consume most of our waking moments.
-
AP Exclusive: Calif. exchange granted secrecy
A California law that created an agency to oversee national health care reforms granted it broad authority to conceal spending on the contractors that will perform most of its functions, potentially shielding the public from seeing how hundreds of millions of dollars are spent.
-
Drugmakers, health groups bring poor girls vaccine
Two multinational drugmakers are teaming up with top global health groups to protect millions of girls in the world's poorest countries from deadly cervical cancer.
-
Study: Fish oil doesn’t help prevent heart attacks
Eating fish is good for your heart but taking fish oil capsules does not help people at high risk of heart problems who are already taking medicines to prevent them, a large study in Italy found.
-
Most and least-fit states in the U.S.
A new report released by the Centers for Disease Control highlights adult fitness levels based on participation in aerobic and muscle-building activities. Find out which states came in with the fittest and least-fit populations.
-
Bashful? Buy the little blue pill online
Men who are bashful about needing help in the bedroom no longer have to go to the drugstore to buy that little blue pill.
-
FDA wants cancer warnings on tanning beds
Indoor tanning beds would come with new warnings about the risk of cancer and be subject to more stringent federal oversight under a proposal unveiled Monday by the Food and Drug Administration.
-
The Lifefirst family
Young Vincent Karolewics dreamed of becoming a naval fighter pilot.
- More Health Headlines
-
Raw: Train Derails After Overpass Collapse
Raw: Rescues From San Antonio Flooding
Raw: French Soldier Stabbed in Throat Near Paris
Mayor: Person Killed in San Antonio Flooding
Raw: Apple 1 Computer Sells for More Than $650k
Hagel Urges Cadets to End Scourge of Sex Assault
Raw: Gay Rights Activists March in Ukraine
Bus Fire Kills 16 Children, Teacher in Pakistan
Raw: Pakistan Election Results Protested
Raw: Trucker Bumps I-5 Bridge Before Collapse
Raw: Texas Deputy Shot by Colo. Suspect Honored
Major Detours Following Wash. Bridge Collapse
American Held in Grisly Czech Murders
Raw: Jersey Shore Reopens for Summer
UK-bound Pakistan Plane Diverted, 2 Men Arrested
